Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemiaã- A Post-Marketing Survey (J-POSSIBLE).

Kiyosue, Arihiro; Yasuda, Satoshi; Tomura, Akiyoshi; Usami, Makiko; Arai, Hidenori

Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemiaã- A Post-Marketing Survey (J-POSSIBLE).

Kiyosue, Arihiro; Yasuda, Satoshi; Tomura, Akiyoshi; Usami, Makiko; Arai, Hidenori.

Kiyosue A; Moriyama Memorial Hospital, Cardiovascular Center.
Yasuda S; Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine.
Tomura A; General Medicines Medical, Sanofi.
Usami M; Post-Authorization Regulatory Studies, Sanofi.
Arai H; National Center for Geriatrics and Gerontology.

Circ J ; 87(6): 834-846, 2023 05 25.

Article en En | MEDLINE | ID: mdl-36631082

Asunto(s)

Anticolesterolemiantes; Hipercolesterolemia; Hiperlipidemias; Hiperlipoproteinemia Tipo II; Humanos; Hipercolesterolemia/tratamiento farmacológico; Proproteína Convertasa 9; Método Doble Ciego; Hiperlipoproteinemia Tipo II/tratamiento farmacológico; LDL-Colesterol; Antivirales/uso terapéutico; Subtilisinas/uso terapéutico; Anticolesterolemiantes/efectos adversos; Resultado del Tratamiento

Palabras clave

Alirocumab; Familial hypercholesterolemia; Lipid-lowering therapy; PCSK9 inhibitor; Post-marketing survey

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hipercolesterolemia / Hiperlipoproteinemia Tipo II / Hiperlipidemias / Anticolesterolemiantes Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google